Company

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts
Clinical trial resultsCSPC Pharmaceutical

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts

CSPC Pharmaceutical Group Limited (HKG: 1093) announced in a voluntary announcement that it will present the latest updates from 8 clinical trials at the European Society for Medical Oncology (ESMO)…

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Product approvalsSHA: 688108

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Cell-therapyFinance

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Huadong MedicineProduct approvals

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

GenentechRecursion

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Show More